勃林格殷格翰收购生物制药公司 Abexxa Biologics

2021-09-26 勃林格殷格翰 勃林格殷格翰

德国制药公司勃林格殷格翰近日宣布收购生物制药公司 Abexxa Biologics。Abexxa Biologics在免疫肿瘤和肿瘤研究领域采用新方法开发下一代精准药物以彻底改变癌症的治疗方式。此次收

德国制药公司勃林格殷格翰近日宣布收购生物制药公司 Abexxa Biologics。Abexxa Biologics在免疫肿瘤和肿瘤研究领域采用新方法开发下一代精准药物以彻底改变癌症的治疗方式。此次收购将使勃林格殷格翰能够利用 Abexxa 靶向细胞内部(非细胞膜上表达)的癌症特异性蛋白质方面的专长,并扩展了潜在癌症抗原靶标范围。尤其是Abexxa 的技术可能会推动癌症免疫疗法的发展,这些疗法将对更广泛的患者和癌症类型有效。

勃林格殷格翰公司高级副总裁、全球发现研究负责人Clive R. Wood博士表示:“收购 Abexxa 加强了我们对肿瘤抗原发现和靶向细胞内抗原新方法的承诺。他们在抗原发现和新型抗体生成方面的尖端知识和技术是对我们现有方法的有力地补充,我们已经成功应用这些方法以实现癌细胞的靶向免疫。通过扩展与新的细胞内肿瘤抗原结合的抗体产品管线,我们正在努力为癌症患者开发独特和广泛适用的新免疫治疗方法。”

2016 年,勃林格殷格翰风险基金(专注于投资开创性疗法和数字健康疗法的公司部门)授予 Abexxa 初始投资资金。同年晚些时候,Abexxa 获得了勃林格殷格翰的创新大奖,该奖项旨在促进公司业务增长并奖励致力于创新的新公司。赢得该奖项使得 Abexxa能将业务运营扩展至马萨诸塞州剑桥的共享实验室,以继续其研究。勃林格殷格翰对 Abexxa 的投资展示了公司如何寻求在领先的生物技术社区(包括德克萨斯州达拉斯-沃思堡地区)促进创新。

 “2016 年来自勃林格殷格翰风险基金的投资对 Abexxa 来说是一个决定性的时刻。”Abexxa 联合创始人兼首席执行官 Debra Wawro Weidanz 说。

 “勃林格殷格翰此次收购使得我们的团队能够利用公司在免疫肿瘤和抗体开发方面的专长和能力,并有机会将 Abexxa 的技术转化为临床资产。” Abexxa 联合创始人和兼CSO Jon Weidanz 博士说。

此次交易是一系列战略收购和合作中最新的一笔,这些收购和合作加强了勃林格殷格翰整体的肿瘤策略,将癌症免疫和癌细胞定向疗法结合起来抗击癌症。这一战略通过在癌症疫苗、溶瘤病毒、T 细胞衔接器、抗体药物偶联物 (ADC) 以及骨髓和基质细胞调节剂方面开发领先资产和强大的能力,进一步加强了勃林格殷格翰在肿瘤领域的地位。通过将公司世界一流的内部研发能力与 Abexxa 等高度创新的生物技术公司的研发相结合,勃林格殷格翰正在开发创新的癌症免疫疗法并加速实现下一代癌症治疗方式。

总交易包括预付款、里程碑付款和其他对价付款。Abexxa 将继续作为勃林格殷格翰家族公司的成员在德克萨斯州阿林顿地区运营,并与勃林格殷格翰美国康涅狄格州里奇菲尔德研究中心的同事进行广泛合作。     

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767866, encodeId=e1d41e67866e4, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 27 09:15:18 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919313, encodeId=baa6191931387, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 21 19:15:18 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387676, encodeId=7ad9138e676f2, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591541, encodeId=02561591541a2, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767866, encodeId=e1d41e67866e4, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 27 09:15:18 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919313, encodeId=baa6191931387, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 21 19:15:18 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387676, encodeId=7ad9138e676f2, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591541, encodeId=02561591541a2, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2022-05-21 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767866, encodeId=e1d41e67866e4, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 27 09:15:18 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919313, encodeId=baa6191931387, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 21 19:15:18 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387676, encodeId=7ad9138e676f2, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591541, encodeId=02561591541a2, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767866, encodeId=e1d41e67866e4, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 27 09:15:18 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919313, encodeId=baa6191931387, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 21 19:15:18 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387676, encodeId=7ad9138e676f2, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591541, encodeId=02561591541a2, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1767866, encodeId=e1d41e67866e4, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 27 09:15:18 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919313, encodeId=baa6191931387, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 21 19:15:18 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387676, encodeId=7ad9138e676f2, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591541, encodeId=02561591541a2, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Tue Sep 28 06:15:18 CST 2021, time=2021-09-28, status=1, ipAttribution=)]

相关资讯

百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物

5月27日,百时美施贵宝宣布与CytomX Therapeutics及Incyte达成一项专注于开发免疫肿瘤治疗药物的协议。百时美施贵宝首席科学官Francis Cuss评论称,“免疫肿瘤对改善癌症治疗方式提供了一个庞大的机遇,百时美施贵宝致力于推进我们免疫肿瘤药物的研究。”根据最初研究合作及许可协议(潜在价值达12亿美元),百时美施贵宝与CytomX将利用后者的Probody平台开发针对多种免疫

纳武利尤单抗获批成为中国治疗头颈部鳞癌的免疫肿瘤药物

近日,PD-1抑制剂纳武利尤单抗(nivolumab,欧狄沃)已正式获得中国国家药品监督管理局(NMPA)批准扩大适应证,适用于治疗接受含铂类方案治疗期间或之后出现疾病进展且肿瘤PD-L1表达阳性(表达PD-L1的肿瘤细胞≥1%)的复发性或转移性头颈部鳞癌(SCCHN)患者。

多方协力,首批免疫肿瘤药物抵华,应用场景揭秘

病不待药,更何况是“病来如山倒”的癌症,一分一秒都是与死亡的博弈和赛跑。在癌症患者及家属的急迫需求下,近两年,中国政府制定了一系列加快药品进口审评审批的政策,这些政策纷纷在产业端落地,正从“白纸黑字”转变为患者实惠。近期,PD-1免疫检查点抑制剂纳武利尤单抗注射液获中国国家药品监督管理局颁发的《进口药品注册证》,落地销售端也指日可待,除去什么时候能用之外,对于患者十分关键的问题还有在什么场景能够用